PharmaShots | Incisive News in 3 Shots

Subscribe Now

Adagene

Adagene Entered into an Exclusive License Agreement with Sanofi to Develop Novel Masked Immuno-Oncology Antibody

Adagene Entered into an Exclusive License Agreement with Sanofi to Develop Novel Masked Immuno-Oncology Antibody

March 2, 2022

Adagene Reports First Patient Dosing of ADG106 + ADG116 in P-Ib/II (ADG116-1003) Trial for the Treatment of Solid Tumors

Adagene Reports First Patient Dosing of ADG106 + ADG116 in P-Ib/II (ADG116-1003) Trial for the Treatment of Solid Tumors

January 28, 2022

PharmaShots Weekly Snapshots (August 16 - 20, 2021)

PharmaShots Weekly Snapshots (August 16 - 20, 2021)

August 20, 2021

Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and Hematological Malignancies

Merck Enters in Third Clinical Trial Collaboration with Adagene to Advance ADG106 + Keytruda (pembrolizumab) for Solid Tumors and...

August 19, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us